Navigation Links
Sagent Pharmaceuticals to Present at Piper Jaffray Health Care Conference
Date:11/23/2009

SCHAUMBURG, Ill., Nov. 23 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company with a focus on injectable products, today announced that Jeffery M. Yordon, chief executive officer, founder and chairman of the board of Sagent Pharmaceuticals, will present at the 21st Annual Piper Jaffray Health Care Conference on Tuesday, December 1, 2009 at 9:30am eastern time at the New York Palace Hotel in New York City, NY.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit www.SagentPharma.com.

SOURCE Sagent Pharmaceuticals, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
2. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
3. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)...  CARsgen, a leader in the development of Chimeric ... variety of cancers, today announced the completion of a ... China -based healthcare private equity fund.   ... development of new therapeutics for liver, lung, stomach and ... Shanghai Renji Hospital, the company plans to initiate clinical ...
(Date:11/26/2014)... Nov. 26, 2014 The medical magnetic ... rate of 4%, with world market revenues for ... MRI and other types of medical imaging have ... of numerous medical conditions in children and adults, ... Kalorama,s report, Medical Imaging Markets , analyzes ...
(Date:11/26/2014)... DALLAS , November 25, 2014 ... Surgical Instruments Market by Power Source (Electric, Battery, ... Console, Cables, Blade, Burr, Cart), by Application (Orthopedic, ... 2019" published by MarketsandMarkets, the global Powered Surgical Instruments ... to $1.6 Billion in 2014 and is expected ...
Breaking Medicine Technology:CARsgen Completes Series A Financing 2Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4
(Date:11/26/2014)... Bunion Bootie, the newest and best ... early celebration of the early holiday shopping season. Starting ... the promotional price of $29.95 each (normally $33.95 ea). ... any automatic discounts applied when buying more than one ... for complete details. It’s simple: purchasing more Bunion Booties ...
(Date:11/26/2014)... November 26, 2014 Louisiana Back ... and specialists in minimally invasive spine surgery, announces ... into the rapidly growing provider network of orthopedic ... addition coincides with the network’s continuing success providing ... for Louisiana residents who are suffering from orthopedic ...
(Date:11/26/2014)... 2014 Sonoran Vein and Endovascular ... the Distinguished Preceptorship Award from The American ... in the advancement of nurse practitioners. The Distinguished ... who had made a significant contribution toward increasing ... Association of Nurse Practitioners (AANP) is the largest ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Youngsters who enter puberty ... study suggests. Early puberty was linked with a ... self-image and high anxiety levels, according to the researchers. ... as conflict with family and peers, and having friends ... found. Although the study found an association between ...
(Date:11/26/2014)... -- Teens prescribed anti-anxiety or sleep medications are ... other teens, a new study warns. The ... assessments on teenagers before prescribing these drugs to ... don,t realize the abuse potential," said lead researcher ... Michigan School of Nursing. "These drugs produce highly ...
Breaking Medicine News(10 mins):Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2
... 19 Healthcare,Technologies Ltd. (NASDAQ: HCTL ), announced ... scheduled for September 30,2007, will be held on December ... Arnon & Co., 1 Azrieli Center, Round Tower, 47th ... be asked to approve the previously,announced Asset Purchase Agreement ...
... may lower sperm count" do not tell the whole ... from the Harvard,School of Public Health in Boston presented ... was based on recollected intake,of soyfoods and not on ... issues, thus I feel the results should be viewed ...
... 18 West Pharmaceutical,Services, Inc. (NYSE: WST ... that it has decided to discontinue marketing the,Exubera ... the,Company,s customer, Nektar Therapeutics, Inc. The Company,s Tech ... Exubera inhalation device for Nektar. "We were ...
... Blocks inflammatory activity of two immune system molecules, researchers ... new twist on an old theory of drug treatment ... trial, a California company reports. , The idea is ... believed to play a major role in asthma by ...
... Republican Whip,Roy Blunt (Mo.) issued the following statement today ... the State,Children,s Health Insurance Program (SCHIP) to children from ... "Today,s vote brings to a close what,s been a ... their energy to scoring,political points, and none of it ...
... 18 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI;,TSX: QLT) ... of,privately held ForSight Newco II, Inc. Through this ... to commercialize,ForSight Newco II,s proprietary ocular punctal plug ... development efforts in this program. "We are ...
Cached Medicine News:Health News:Healthcare Technologies Announces New Date for the Shareholders Meeting to Approve the Nexgen Biofuels Transaction 2Health News:Healthcare Technologies Announces New Date for the Shareholders Meeting to Approve the Nexgen Biofuels Transaction 3Health News:Real Men Eat Soy: The Truth about Soy and Sperm Count 2Health News:West Pharmaceutical Services Issues Statement on Exubera 2Health News:West Pharmaceutical Services Issues Statement on Exubera 3Health News:West Pharmaceutical Services Issues Statement on Exubera 4Health News:New Drug Eases Asthma Symptoms 2Health News:New Drug Eases Asthma Symptoms 3Health News:QLT Completes Acquisition of ForSight Newco II, Inc. 2Health News:QLT Completes Acquisition of ForSight Newco II, Inc. 3
The new CR6-45NM non-mydriatic retinal camera is an ideal diagnostic tool for ophthalmologists, optometrists and other medical professionals, especially when it comes to detecting and monitoring diab...
An ideal choice for film photography. The new TRC-50FXC provides 35mm color and Polaroid capability....
Digital imaging for optical screening: Diabetes, glaucoma macular degeneration, and other retinal disease....
All welded construction for strength and durability. Choice of stainless steel or chrome plated models....
Medicine Products: